GB9608649D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- GB9608649D0 GB9608649D0 GBGB9608649.1A GB9608649A GB9608649D0 GB 9608649 D0 GB9608649 D0 GB 9608649D0 GB 9608649 A GB9608649 A GB 9608649A GB 9608649 D0 GB9608649 D0 GB 9608649D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- novel compounds
- novel
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9608649.1A GB9608649D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
JP9538603A JP2000509063A (en) | 1996-04-26 | 1997-04-28 | Azetidinone derivatives for the treatment of atherosclerosis |
PCT/EP1997/002286 WO1997041099A1 (en) | 1996-04-26 | 1997-04-28 | Azetidinone derivatives for the treatment of atherosclerosis |
EP97921853A EP0900199A1 (en) | 1996-04-26 | 1997-04-28 | Azetidinone derivatives for the treatment of atherosclerosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9608649.1A GB9608649D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
GB9608649D0 true GB9608649D0 (en) | 1996-07-03 |
Family
ID=10792682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB9608649.1A Pending GB9608649D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0900199A1 (en) |
JP (1) | JP2000509063A (en) |
GB (1) | GB9608649D0 (en) |
WO (1) | WO1997041099A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060805A1 (en) | 2000-02-16 | 2001-08-23 | Smithkline Beecham P.L.C. | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
ES2298753T3 (en) | 2003-05-07 | 2008-05-16 | The University Court Of The University Of Aberdeen | KETONES AND KETONES REDUCED AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OSEAS DISEASES. |
KR101461659B1 (en) | 2007-05-11 | 2014-11-17 | 토마스 제퍼슨 유니버시티 | Methods of treatment and prevention of neurodegenerative diseases and disorders |
WO2008141176A1 (en) | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
JP5886310B2 (en) | 2010-12-06 | 2016-03-16 | グラクソ グループ リミテッドGlaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
CN103619831B (en) | 2011-06-27 | 2016-05-04 | 中国科学院上海药物研究所 | Azole heterocyclic compound, its preparation method, pharmaceutical composition and purposes |
RU2014107486A (en) | 2011-07-27 | 2015-09-10 | Глэксо Груп Лимитед | Bicyclic pyrimidone compounds |
BR112014001665A2 (en) | 2011-07-27 | 2017-02-14 | Glaxo Group Ltd | 2,3-dihydroimidazo [1,2-c] pyrimidin-5 (1h) -one compounds used as lp-plaz inhibitors |
JP2016505053A (en) | 2013-01-25 | 2016-02-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2 |
UY35276A (en) | 2013-01-25 | 2014-08-29 | Glaxosmithkline Ip Dev Ltd | New compounds that inhibit the activity of Lp-PLA2 |
WO2014114248A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
EP3713907A4 (en) * | 2019-02-15 | 2020-11-25 | Fujian Yongjing Technology Co., Ltd | New process for manufacture of fluorinated benzenes and fluorinated benzophenones, and derivatives thereof |
CN112778331B (en) | 2019-11-09 | 2022-07-05 | 上海赛默罗生物科技有限公司 | Tricyclic dihydroimidazopyrimidinone derivatives, preparation method, pharmaceutical composition and application thereof |
CN115304620A (en) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
PL320937A1 (en) * | 1994-12-22 | 1997-11-10 | Smithkline Beecham Plc | Substituted azetidin-2-ones for treating arterial atheromatosis |
PL324240A1 (en) * | 1995-07-01 | 1998-05-11 | Smithkline Beecham Plc | Derivatives of azetidinone for treating atherosclerosis |
-
1996
- 1996-04-26 GB GBGB9608649.1A patent/GB9608649D0/en active Pending
-
1997
- 1997-04-28 JP JP9538603A patent/JP2000509063A/en active Pending
- 1997-04-28 EP EP97921853A patent/EP0900199A1/en not_active Withdrawn
- 1997-04-28 WO PCT/EP1997/002286 patent/WO1997041099A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0900199A1 (en) | 1999-03-10 |
JP2000509063A (en) | 2000-07-18 |
WO1997041099A1 (en) | 1997-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0914330A4 (en) | Novel compounds | |
EP0961618A4 (en) | Novel compounds | |
EP0909181A4 (en) | Novel compounds | |
GB9601067D0 (en) | Novel compounds | |
EP0907375A4 (en) | Novel compounds | |
GB9608649D0 (en) | Novel compounds | |
AP9701047A0 (en) | Novel compounds | |
GB9605945D0 (en) | Novel compounds | |
GB9601041D0 (en) | Novel compounds | |
AP9701037A0 (en) | Novel compounds | |
GB9604045D0 (en) | Novel compounds | |
GB9619072D0 (en) | Novel compounds | |
GB9605381D0 (en) | Novel compounds | |
GB9601069D0 (en) | Novel compounds | |
GB9605883D0 (en) | Novel compounds | |
EP0954525A4 (en) | Novel compounds | |
GB9601068D0 (en) | Novel compounds | |
EP0907377A4 (en) | Novel compounds | |
GB9601066D0 (en) | Novel compounds | |
GB9601099D0 (en) | Novel compounds | |
GB9604582D0 (en) | Novel compounds | |
GB9606198D0 (en) | Novel compounds | |
GB9605155D0 (en) | Novel compounds | |
GB9601096D0 (en) | Novel compounds | |
GB9605153D0 (en) | Novel compounds |